HK Stock Market Move | SBP GROUP (01177) rose more than 4% and deepened its exclusive strategic cooperation with GSK, obtaining two innovative respiratory drugs.

date
10:00 09/07/2026
avatar
GMT Eight
China Biopharmaceuticals (01177) surged over 4% again, as of the time of reporting, increasing by 4.36% to 5.02 Hong Kong dollars, with a turnover of 146 million Hong Kong dollars.
SBP GROUP (01177) rose by more than 4%, rising by 4.36% to HK$5.02 by the time of publication, with a turnover of HK$146 million. On the news front, on July 8th, SBP GROUP announced that its subsidiary, Zhejiang Tianqing Pharmaceutical Group Co., Ltd. ("Zhejiang Tianqing"), has further deepened its exclusive strategic cooperation with GlaxoSmithKline ("GSK") reached in May 2026 to promote two blockbuster innovative respiratory drugs for more Chinese patients. This cooperation is another important milestone in the strategic partnership between the Group and GSK, marking the expansion of cooperation from liver disease to respiratory system diseases. Under the agreement, the Group will obtain the commercial rights of two innovative respiratory drugs from GSK: fluticasone furoate inhalation powder (trade name: Trelegy Ellipta) and umeclidinium/vilanterol inhalation powder (trade name: Anoro Ellipta) in mainland China. The Group will be responsible for the import, distribution, hospital access, promotion, and non-promotion activities of these products in mainland China, and all sales revenue generated by these products will be recorded as Zhejiang Tianqing's operating income.